Fluor trades at 2.07x earnings with 99.65% ROE, signaling undervaluation.

Fluor (FLR) tops hidden gems with a 95/100 valuation score, P/E of 2.02, P/B of 1.18, and exceptional ROE of 99.65%.

These hidden gem small-caps like CPRX, TRIN, FLR, NUTX, and KRYS stand out with compelling valuations (P/E as low as 2.02), high ROE (up to 99.65%), and strong scores, signaling quality amid inefficiencies. Small-caps often evade institutional scrutiny and analyst coverage—40% have ≤3 analysts—fostering mispricings that active analysis exploits. As awareness grows, their robust fundamentals could drive re-rating.

• CPRX Market Cap: $2.6B, strong growth with Q3 2025 revenue $148.4M up 15.3% YoY

• CPRX P/E: 12.73, attractive vs healthcare peers averaging higher multiples

• CPRX ROE: 28.49%, solid profitability with Q3 EPS $0.68 beating estimates by 106%

• TRIN Market Cap: $1.1B, smaller scale in financial services sector

• TRIN P/E: 6.62, deeply undervalued indicating potential bargain pricing

• FLR Valuation Score: 95/100, standout high score across group average ~69/100

• NUTX P/E: 2.38, lowest in list signaling deep value in healthcare

Top Valuation Scores FLR and NUTX lead with exceptional valuation scores of 95/100 and 73/100, signaling strong undervaluation potential per value screens. FLR's P/E of 2.02 and NUTX's 2.38 far beat Graham's ≤9 benchmark, offering margin of safety. Insight: Ultra-low P/Es paired with high scores highlight market overlooks in industrials and healthcare.

Low P/B Leaders TRIN and FLR shine with P/B ratios of 1.18 each, aligning precisely with Graham's ≤1.2 threshold for asset-backed value. Both small/mid-caps ($1.1B-$7.4B) trade near book value, minimizing downside risk. Insight: Such ratios suggest stocks priced below net assets, classic hidden gems for patient investors.

ROE Powerhouses FLR boasts a standout ROE of 99.65%, with NUTX at 78.92%, indicating superior capital efficiency. These exceed peers like CPRX's 28.49%, reflecting quality per stock screen quality filters. Insight: High ROE in undervalued names points to robust profitability overlooked by broader markets.

Healthcare Dominance Three of five stocks (CPRX, NUTX, KRYS) hail from healthcare, spanning $637M-$5.7B caps with scores 44-73/100. NUTX's P/E 2.38 and CPRX's 12.73 show value variety in the sector. Insight: Sector concentration offers diversified exposure to growth while meeting value criteria like low P/E.

(198 words)

FLR and NUTX stand out as compelling small-cap value plays with ultralow P/E ratios (2.02 and 2.38) paired with exceptional ROE above 78%, signaling strong efficiency amid cheap valuations. Small caps overall remain historically undervalued relative to large caps, with earnings growth converging. Watch sector catalysts like biotech M&A, industrials reshoring/AI infrastructure, and 2026 earnings acceleration for rotation momentum.